Free tool
FAERS Monitor: Xiidra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208073 or its brand name (Xiidra, Lifitegrast). Reports on generic versions are filed under their own applications.
Reports
16,505
Serious
2,977
18% of reports
Hospitalization
678
Death reported
298
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye irritation2,780
- vision blurred2,679
- drug ineffective1,629
- eye pain1,460
- instillation site pain1,283
- dry eye1,187
- dysgeusia1,118
- instillation site reaction1,019
- ocular hyperaemia707
- lacrimation increased636
- headache629
- visual impairment587
- product dose omission issue454
- eye pruritus446
- eye discharge403
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 4 |
| 2016 | 630 |
| 2017 | 1,846 |
| 2018 | 1,538 |
| 2019 | 1,189 |
| 2020 | 1,976 |
| 2021 | 2,129 |
| 2022 | 2,489 |
| 2023 | 1,922 |
| 2024 | 1,097 |
| 2025 | 985 |
| 2026 | 700 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,654 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| instillation site reactionSignal | 1,019 | 18293.5 | 14388.9 | 1,212,975 |
| instillation site painSignal | 1,283 | 1366.2 | 1264.6 | 844,227 |
| eye irritationSignal | 2,780 | 64.6 | 62.4 | 166,117 |
| eye dischargeSignal | 403 | 51.4 | 46.6 | 19,097 |
| eye painSignal | 1,460 | 33.8 | 32.2 | 45,395 |
| dry eyeSignal | 1,187 | 31.0 | 29.3 | 33,713 |
| lacrimation increasedSignal | 636 | 27.4 | 25.3 | 15,820 |
| vision blurredSignal | 2,679 | 25.3 | 24.5 | 61,786 |
| dysgeusiaSignal | 1,118 | 19.5 | 18.4 | 19,328 |
| ocular hyperaemiaSignal | 707 | 19.3 | 17.9 | 12,064 |
| eye pruritusSignal | 446 | 17.1 | 15.6 | 6,679 |
| visual impairmentSignal | 587 | 6.1 | 5.6 | 2,478 |
| product dose omission issue | 454 | 2.0 | 1.8 | 218 |
| drug ineffective | 1,629 | 1.6 | 1.5 | 365 |
| headache | 629 | 1.3 | 1.2 | 39 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.